- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Ambrosia Raises $100M for Next-Gen Small Molecule GLP-1 Drugs
The Colorado biotech aims to surpass first-generation oral GLP-1 pills with its AI-powered molecule design platform.
Apr. 1, 2026 at 12:38pm
Got story updates? Submit your updates here. ›
Ambrosia Biosciences has raised $100 million in a Series B funding round to advance its pipeline of small molecule GLP-1 agonists, an alternative to the current peptide-based drugs like Ozempic and Mounjaro. The company plans to use the funds to initiate a Phase 1 study of its lead asset and further develop its broader cardiometabolic portfolio, which also includes candidates targeting GIP and amylin pathways.
Why it matters
While peptide GLP-1 drugs have become the dominant approach, Ambrosia believes small molecules offer key advantages like improved oral bioavailability and manufacturing. As the field evolves beyond first-generation molecules, Ambrosia aims to leverage its AI-driven platform to design differentiated small molecule GLP-1 agonists with enhanced potency and combinability.
The details
Ambrosia's $100 million Series B round was co-led by new investors Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital. The company will use the funds to advance its lead small molecule GLP-1 agonist into Phase 1 trials and further develop its broader pipeline targeting other cardiometabolic pathways like GIP and amylin. Ambrosia's approach focuses on the structural biology of the target receptor and utilizes an AI-powered molecule design engine to generate differentiated assets, with an emphasis on improved potency, 24-hour target coverage, and combinability compared to first-generation oral GLP-1 drugs.
- In late December 2025, the FDA approved a pill version of Novo's Wegovy, bringing peptide GLP-1s to the oral arena.
- Eli Lilly's weight loss pill orforglipron, a small molecule GLP-1 agonist, is currently under FDA review with a decision expected in the coming days.
The players
Ambrosia Biosciences
A Colorado-based biotech company developing a pipeline of small molecule drugs targeting cardiometabolic pathways including GLP-1, GIP, and amylin.
Nick Traggis
CEO of Ambrosia Biosciences.
Novo Nordisk
A pharmaceutical company that markets the peptide GLP-1 agonists Ozempic and Wegovy.
Eli Lilly
A pharmaceutical company that markets the peptide GLP-1/GIP dual agonist Mounjaro and is developing the small molecule GLP-1 agonist orforglipron.
Structure Therapeutics
A biotech company developing the small molecule GLP-1 agonist aleniglipron.
What they’re saying
“As the field moves beyond first-generation molecules, we see a meaningful opportunity for differentiated small molecule modulators that are designed with combinability in mind.”
— Nick Traggis, CEO, Ambrosia Biosciences
What’s next
Ambrosia plans to initiate a Phase 1 clinical trial for its lead small molecule GLP-1 agonist in the coming months. Structure Therapeutics also intends to launch a late-stage program for its small molecule candidate aleniglipron later this year.
The takeaway
The race is on to develop the next generation of oral GLP-1 agonists, with both large pharmaceutical companies and emerging biotechs pursuing small molecule approaches that could offer advantages over first-generation peptide-based drugs. Ambrosia's AI-powered platform aims to generate differentiated assets that could surpass current oral GLP-1 options.
